CY1125690T1 - Αντιμυκητιασικα μεσα με ενισχυμενηδραστηριοτητα σε οξινο ρη - Google Patents

Αντιμυκητιασικα μεσα με ενισχυμενηδραστηριοτητα σε οξινο ρη

Info

Publication number
CY1125690T1
CY1125690T1 CY20221100767T CY221100767T CY1125690T1 CY 1125690 T1 CY1125690 T1 CY 1125690T1 CY 20221100767 T CY20221100767 T CY 20221100767T CY 221100767 T CY221100767 T CY 221100767T CY 1125690 T1 CY1125690 T1 CY 1125690T1
Authority
CY
Cyprus
Prior art keywords
conditions
acidic
enfumafungin
prevention
treatment
Prior art date
Application number
CY20221100767T
Other languages
Greek (el)
English (en)
Inventor
David A. ANGULO GONZALEZ
Original Assignee
Scynexis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1125690(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scynexis, Inc. filed Critical Scynexis, Inc.
Publication of CY1125690T1 publication Critical patent/CY1125690T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20221100767T 2017-08-04 2022-12-06 Αντιμυκητιασικα μεσα με ενισχυμενηδραστηριοτητα σε οξινο ρη CY1125690T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762541370P 2017-08-04 2017-08-04

Publications (1)

Publication Number Publication Date
CY1125690T1 true CY1125690T1 (el) 2026-02-25

Family

ID=63209698

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100767T CY1125690T1 (el) 2017-08-04 2022-12-06 Αντιμυκητιασικα μεσα με ενισχυμενηδραστηριοτητα σε οξινο ρη

Country Status (26)

Country Link
US (3) US11534433B2 (cg-RX-API-DMAC7.html)
EP (3) EP4169514B1 (cg-RX-API-DMAC7.html)
JP (1) JP7214714B2 (cg-RX-API-DMAC7.html)
KR (1) KR102807716B1 (cg-RX-API-DMAC7.html)
CN (2) CN118542868A (cg-RX-API-DMAC7.html)
AU (2) AU2018309718B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020002290A2 (cg-RX-API-DMAC7.html)
CA (1) CA3071940A1 (cg-RX-API-DMAC7.html)
CY (1) CY1125690T1 (cg-RX-API-DMAC7.html)
DK (1) DK3661503T3 (cg-RX-API-DMAC7.html)
EA (1) EA202090445A1 (cg-RX-API-DMAC7.html)
ES (2) ES2932658T3 (cg-RX-API-DMAC7.html)
FI (1) FI3661503T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221414T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060508T2 (cg-RX-API-DMAC7.html)
LT (1) LT3661503T (cg-RX-API-DMAC7.html)
MA (1) MA49751B1 (cg-RX-API-DMAC7.html)
MD (1) MD3661503T2 (cg-RX-API-DMAC7.html)
MX (1) MX2020001399A (cg-RX-API-DMAC7.html)
PL (1) PL3661503T3 (cg-RX-API-DMAC7.html)
PT (1) PT3661503T (cg-RX-API-DMAC7.html)
RS (1) RS63746B1 (cg-RX-API-DMAC7.html)
SI (1) SI3661503T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200461T1 (cg-RX-API-DMAC7.html)
TW (1) TWI805600B (cg-RX-API-DMAC7.html)
WO (1) WO2019028034A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020228036B2 (en) * 2019-02-27 2025-08-07 Scynexis, Inc. Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia
AU2020276595B2 (en) * 2019-05-16 2025-12-04 Scynexis, Inc. Antifungal Agents for Candida Auris Decolonization
WO2022140646A1 (en) * 2020-12-26 2022-06-30 Mycovia Pharmaceuticals, Inc Dosing regimen for oteseconazole

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
ES2402659T3 (es) 2006-04-03 2013-05-07 Merck Sharp & Dohme Corp. Derivados de enfumafungina como agentes antifúngicos
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
BRPI0912074B1 (pt) * 2008-08-12 2021-08-03 Merck Sharp & Dohme Corp Composto e composição farmacêutica
PT3247711T (pt) 2015-01-19 2022-05-16 Scynexis Inc Novos sais e polimorfos de scy-078
JP7263313B2 (ja) * 2017-04-10 2023-04-24 サイネクシス,インコーポレーテッド 併用される抗真菌剤

Also Published As

Publication number Publication date
US20200390751A1 (en) 2020-12-17
CN118542868A (zh) 2024-08-27
EP4169514B1 (en) 2026-01-28
SMT202200461T1 (it) 2023-01-13
MD3661503T2 (ro) 2023-01-31
KR20200044823A (ko) 2020-04-29
CA3071940A1 (en) 2019-02-07
AU2024227501A1 (en) 2024-11-07
TWI805600B (zh) 2023-06-21
BR112020002290A2 (pt) 2020-09-08
US20260000656A1 (en) 2026-01-01
HUE060508T2 (hu) 2023-03-28
JP7214714B2 (ja) 2023-01-30
HRP20221414T1 (hr) 2023-01-20
PL3661503T3 (pl) 2023-01-09
CN111093655A (zh) 2020-05-01
AU2018309718A1 (en) 2020-02-27
SI3661503T1 (sl) 2023-01-31
MX2020001399A (es) 2020-08-06
MA49751B1 (fr) 2022-12-30
TW201919476A (zh) 2019-06-01
LT3661503T (lt) 2022-12-12
WO2019028034A1 (en) 2019-02-07
PT3661503T (pt) 2022-12-13
RS63746B1 (sr) 2022-12-30
EP4169514A1 (en) 2023-04-26
EP3661503A1 (en) 2020-06-10
JP2020529999A (ja) 2020-10-15
DK3661503T3 (da) 2022-12-12
FI3661503T3 (fi) 2022-12-15
MA49751A (fr) 2020-06-10
US20230364067A1 (en) 2023-11-16
KR102807716B1 (ko) 2025-05-13
EP3661503B1 (en) 2022-09-07
EP4732902A3 (en) 2026-07-22
US11534433B2 (en) 2022-12-27
ES2932658T3 (es) 2023-01-23
EA202090445A1 (ru) 2020-06-23
EP4732902A2 (en) 2026-04-29
AU2018309718B2 (en) 2024-07-25
EP4169514C0 (en) 2026-01-28
ES3068719T3 (en) 2026-06-02

Similar Documents

Publication Publication Date Title
CY1124206T1 (el) Αναστολεις πυριδοπυριμδινονης cdk2/4/6
JOP20210001B1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
CY1125004T1 (el) Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας
DOP2020000018A (es) Amidas heterocíclicas útiles como moduladores de proteínas
CY1122614T1 (el) 11-υδροξυλ-6-υποκατεστημενα-παραγωγα χολικων οξεων και συζευγματα αμινοξεων αυτων ως ρυθμιστες υποδοχεων χ φαρνεσοειδων
EA202191051A1 (ru) Ингибитор аврора-киназы a для применения для лечения нейробластомы
PH12017501326A1 (en) Tgf-� inhibitors
CY1121334T1 (el) Αναστολεας κινασης aurora a
JOP20210083B1 (ar) مترافقات عقار جسم مضاد تشتمل على مشتقات إكتيناسكيدين
CY1121855T1 (el) Παραγωγα βενζιμιδαζολιου ως αναστολεις βρωμοπεδιου
EA202193015A1 (ru) Ингибиторы cdk
MX2023000418A (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia.
BR112018074268A2 (pt) pastas dentais terapêuticas e métodos e kits relacionados
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
JOP20190130A1 (ar) مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
EA201690669A8 (ru) Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
CY1124643T1 (el) Νεα ενωση και φαρμακευτικα αποδεκτο αλας αυτης
BR112018074985A2 (pt) composições antibacterianas
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
CL2018001407A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
MX2019006768A (es) Peptidos antimicrobianos.
MX2021006522A (es) Adsorbatos.